Verve Therapeutics’ (VERV) Buy Rating Reiterated at Guggenheim

Guggenheim reiterated their buy rating on shares of Verve Therapeutics (NASDAQ:VERV) in a research report report published on Tuesday morning,Benzinga reports.

Other equities research analysts have also issued reports about the company. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Verve Therapeutics in a research note on Tuesday. William Blair reaffirmed an “outperform” rating on shares of Verve Therapeutics in a research note on Friday, February 21st. Finally, Royal Bank of Canada reduced their target price on shares of Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a research report on Tuesday, March 4th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Verve Therapeutics has a consensus rating of “Buy” and an average target price of $25.50.

Verve Therapeutics Trading Down 2.2 %

Shares of VERV opened at $5.28 on Tuesday. The firm has a market cap of $468.84 million, a P/E ratio of -2.15 and a beta of 1.77. Verve Therapeutics has a 12 month low of $4.31 and a 12 month high of $13.63. The stock’s 50 day moving average is $6.96 and its two-hundred day moving average is $6.08.

Verve Therapeutics (NASDAQ:VERV) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.14. The company had revenue of $13.08 million during the quarter, compared to analyst estimates of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. Equities research analysts forecast that Verve Therapeutics will post -2.49 EPS for the current year.

Institutional Trading of Verve Therapeutics

Large investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. grew its holdings in shares of Verve Therapeutics by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 17,952 shares of the company’s stock valued at $101,000 after purchasing an additional 1,676 shares during the period. Rhumbline Advisers boosted its holdings in Verve Therapeutics by 1.9% in the 4th quarter. Rhumbline Advisers now owns 111,203 shares of the company’s stock valued at $627,000 after purchasing an additional 2,093 shares during the last quarter. Arizona State Retirement System grew its stake in shares of Verve Therapeutics by 15.8% in the 4th quarter. Arizona State Retirement System now owns 19,593 shares of the company’s stock valued at $111,000 after buying an additional 2,669 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Verve Therapeutics by 5.8% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 50,230 shares of the company’s stock worth $313,000 after buying an additional 2,742 shares during the last quarter. Finally, Invesco Ltd. raised its position in shares of Verve Therapeutics by 5.7% during the 4th quarter. Invesco Ltd. now owns 57,140 shares of the company’s stock valued at $322,000 after buying an additional 3,080 shares during the period. 97.11% of the stock is currently owned by hedge funds and other institutional investors.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.